{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:56:08Z","timestamp":1790916968859,"version":"4.1.0"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>MYH9 is upregulated in various malignancies, but its role in breast cancer chemoresistance remains unclear. We investigated whether MYH9 regulates doxorubicin (ADR) resistance via GRP78 stabilization and PERK pathway modulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      MYH9 expression was analyzed in breast cancer tissues and cell lines by immunohistochemistry and western blot. ADR-resistant MCF-7 and MDA-MB-231 cell lines were established. MYH9 knockdown\/overexpression and GRP78 overexpression were achieved by lentiviral transduction. Protein interactions, degradation assays, PERK signaling, apoptosis, and\n                      <jats:italic>in vivo<\/jats:italic>\n                      drug responses were evaluated.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      MYH9 was significantly upregulated in breast cancer tissues, particularly in triple-negative breast cancer (95.2%), and further elevated in ADR-resistant cells. MYH9 overexpression enhanced ADR tolerance, while knockdown sensitized resistant cells\n                      <jats:italic>in vitro<\/jats:italic>\n                      and\n                      <jats:italic>in vivo<\/jats:italic>\n                      . Mechanistically, MYH9 directly bound GRP78 (but not CALR or GRP94), inhibiting ubiquitin-mediated proteasomal degradation. MYH9 depletion reduced GRP78 levels and activated the PERK pathway (p-eIF2\u03b1, ATF4, CHOP), promoting apoptosis via Bax\/Bad upregulation and Bcl-2 downregulation. ERS induction with thapsigargin enhanced ADR sensitivity, whereas 4-PBA attenuated it. GRP78 overexpression rescued ADR resistance, confirming GRP78 dependency.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>MYH9 confers ADR resistance in breast cancer by stabilizing GRP78 and suppressing PERK-driven apoptosis, identifying the MYH9\/GRP78 axis as a potential therapeutic target for overcoming chemoresistance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1923603","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:41:37Z","timestamp":1790916097000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["MYH9 confers doxorubicin resistance by stabilizing GRP78 and suppressing the PERK signaling-driven apoptotic pathway in breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Jing","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, Ningbo No. 2 Hospital, Wenzhou Medical University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzi","family":"You","sequence":"additional","affiliation":[{"name":"Department if Dermatology, Traditional Chinese Medicine Hospital of Ninghai County","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyi","family":"Zhao","sequence":"additional","affiliation":[{"name":"Health Science Center, Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binlei","family":"Sheng","sequence":"additional","affiliation":[{"name":"School of Medicine, ShaoXing University","place":["ShaoXing, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanqi","family":"Sun","sequence":"additional","affiliation":[{"name":"Health Science Center, Ningbo University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xujun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, Ningbo No. 2 Hospital, Wenzhou Medical University","place":["Ningbo, Zhejiang, China"]},{"name":"Department of Oncology, Ningbo Second Hospital, Ningbo No. 2 Hospital, Wenzhou Medical University","place":["Ningbo, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct Target Ther"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16208","article-title":"A comprehensive overview of metaplastic breast cancer: Features and treatments","volume":"115","author":"Yan","year":"2024","journal-title":"Cancer Sci"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104351","article-title":"Recent strategies to overcome breast cancer resistance","volume":"197","author":"Khan","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"102375","DOI":"10.1016\/j.ctrv.2022.102375","article-title":"Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality","volume":"105","author":"Kerr","year":"2025","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2025.101288","article-title":"Drug resistance in breast cancer: Mechanisms and strategies for management","volume":"83","author":"Wu","year":"2025","journal-title":"Drug Resist Update"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.16202","article-title":"Myosin superfamily members during myelin formation and regeneration","volume":"168","author":"Yamazaki","year":"2024","journal-title":"J Neurochem"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.094300","article-title":"The myosin superfamily at a glance","volume":"125","author":"Hartman","year":"2012","journal-title":"J Cell Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/978-3-030-38062-5_2","article-title":"Myosin structures","volume":"1239","author":"Sweeney","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.gene.2015.10.022","article-title":"Myosin superfamily: The multi-functional and irreplaceable factors in spermatogenesis and testicular tumors","volume":"576","author":"Li","year":"2016","journal-title":"Gene"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2018.04.048","article-title":"MYH9: Structure, functions and role of non-muscle myosin IIA in human disease","volume":"664","author":"Pecci","year":"2018","journal-title":"Gene"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116118","article-title":"MYH9: A key protein involved in tumor progression and virus-related diseases","volume":"171","author":"Liu","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203573","article-title":"SAMD9 promotes postoperative recurrence of esophageal squamous cell carcinoma by stimulating MYH9-mediated GSK3\u03b2\/\u03b2-catenin signaling","volume":"10","author":"Li","year":"2023","journal-title":"Adv Sci (Weinh)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217813","article-title":"CHD4 drives gastric cancer metastasis via MYH9\/GSK3\u03b2\/\u03b2-catenin axis and WNT\/EMT pathway activation","volume":"628","author":"Shi","year":"2025","journal-title":"Cancer Lett"},{"key":"B14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s13058-024-01802-z","article-title":"TMEM120B strengthens breast cancer cell stemness and accelerates chemotherapy resistance via \u03b21-integrin\/FAK-TAZ-mTOR signaling axis by binding to MYH9","volume":"26","author":"Hu","year":"2024","journal-title":"Breast Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.7150\/thno.46001","article-title":"Nuclear MYH9-induced CTNNB1 transcription, targeted by staurosporin, promotes gastric cancer cell anoikis resistance and metastasis","volume":"10","author":"Ye","year":"2020","journal-title":"Theranostics"},{"key":"B16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41392-024-01963-5","article-title":"The p-MYH9\/USP22\/HIF-1\u03b1 axis promotes lenvatinib resistance and cancer stemness in hepatocellular carcinoma","volume":"9","author":"Shan","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/s41420-021-00681-z","article-title":"MYH9 is crucial for stem cell-like properties in non-small cell lung cancer by activating mTOR signaling","volume":"7","author":"Chen","year":"2021","journal-title":"Cell Death Discov"},{"key":"B18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13058-025-01973-3","article-title":"SMYD4 promotes MYH9 ubiquitination through lysine monomethylation modification to inhibit breast cancer progression","volume":"27","author":"Yang","year":"2025","journal-title":"Breast Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1038\/s41419-024-07164-w","article-title":"FATS inhibits the Wnt pathway and induces apoptosis through degradation of MYH9 and enhances sensitivity to paclitaxel in breast cancer","volume":"15","author":"Song","year":"2024","journal-title":"Cell Death Dis"},{"key":"B20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12964-024-01664-0","article-title":"A novel role for KIFC1-MYH9 interaction in triple-negative breast cancer aggressiveness and racial disparity","volume":"22","author":"Garlapati","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-012513-104649","article-title":"The role of endoplasmic reticulum stress in human pathology","volume":"10","author":"Oakes","year":"2015","journal-title":"Annu Rev Pathol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1694102","article-title":"Endoplasmic reticulum stress and unfolded protein response in immune cell function","volume":"16","author":"Matsushima","year":"2025","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/nrm3270","article-title":"The unfolded protein response: controlling cell fate decisions under ER stress and beyond","volume":"13","author":"Hetz","year":"2012","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.critrevonc.2018.05.003","article-title":"The unfolded protein response as a target for anticancer therapeutics","volume":"127","author":"Wang","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cells11040632","article-title":"Drug resistance and endoplasmic reticulum stress in hepatocellular carcinoma","volume":"11","author":"Khaled","year":"2022","journal-title":"Cells"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-025-02232-w","article-title":"ER stress and\/or ER-phagy in drug resistance? Three coincidences are proof","volume":"23","author":"Panda","year":"2025","journal-title":"Cell Commun Signal"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2019.04.022","article-title":"GRP78: A cell's response to stress","volume":"226","author":"Ibrahim","year":"2019","journal-title":"Life Sci"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2303448120","article-title":"ER chaperone GRP78\/BiP translocates to the nucleus under stress and acts as a transcriptional regulator","volume":"120","author":"Liu","year":"2023","journal-title":"Proc Natl Acad Sci USA"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.2174\/1566524016666160523143937","article-title":"The role of the PERK\/eIF2\u03b1\/ATF4\/CHOP signaling pathway in tumor progression during endoplasmic reticulum stress","volume":"16","author":"Rozpedek","year":"2016","journal-title":"Curr Mol Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/deaa180","article-title":"Metformin inhibits testosterone-induced endoplasmic reticulum stress in ovarian granulosa cells via inactivation of p38 MAPK","volume":"35","author":"Jin","year":"2020","journal-title":"Hum Reprod"},{"key":"B31","article-title":"Afatinib down-regulates MCL-1 expression through the PERK-eIF2\u03b1-ATF4 axis and leads to apoptosis in head and neck squamous cell carcinoma","volume":"6","author":"Liu","year":"2016","journal-title":"Am J Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s13346-024-01648-0","article-title":"A comprehensive review on doxorubicin: mechanisms, toxicity, clinical trials, combination therapies and nanoformulations in breast cancer","volume":"15","author":"Bisht","year":"2025","journal-title":"Drug Delivery Transl Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4103\/0973-1482.139267","article-title":"An overview of doxorubicin formulations in cancer therapy","volume":"10","author":"Rivankar","year":"2014","journal-title":"J Cancer Res Ther"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1923603\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:41:41Z","timestamp":1790916101000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1923603\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,2]]},"references-count":33,"alternative-id":["10.3389\/fonc.2026.1923603"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1923603","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,2]]},"article-number":"1923603"}}